AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 13

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Aug 13, 2018	Jones Randal	10% Owner	Sale+OE	1,270	$3.98	$5,054.60	-100%
Jul 31, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	2,855	$4.25	$12,134.32	-
Jul 27, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	28,926	$4.41	$127,576.76	+0.2%
Jul 18, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	30,019	$4.28	$128,405.07	+0.2%
Jul 2, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	18,200	$4.11	$74,757.78	+0.1%
May 23, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$3.78	$189,174.63	+0.3%
May 18, 2018	Greenleaf Peter49	Chief Executive Officer	Buy	12,500	$3.98	$49,750.00	+3.1%
May 17, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	130,000	$3.60	$467,633.87	+0.8%
Apr 23, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	20,000	$3.76	$75,145.91	+0.1%
Apr 18, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	150,000	$3.42	$512,373.04	+0.9%